The pattern of changes in SREBP‐1c and NF‐kB expression was consistent with a report from Nagaya et al21 showing that inflammation persisted, and hepatic lipid deposition and SREBP‐1c expression decreased as NASH progressed. This evidence concerns the gene SREBF1 and metabolic dysfunction-associated steatohepatitis.